JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 13, 2004; DOI: 10.1124/jpet.104.067561


0022-3565/04/3103-1084-1095$20.00
JPET 310:1084-1095, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.067561v1
310/3/1084    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mc Gee, M. M.
Right arrow Articles by Zisterer, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mc Gee, M. M.
Right arrow Articles by Zisterer, D. M.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL

Margaret M. Mc Gee, Lisa M. Greene, Susan Ledwidge, Giuseppe Campiani, Vito Nacci, Mark Lawler, D. Clive Williams, and Daniela M. Zisterer

Department of Biochemistry, Trinity College, Dublin, Ireland (M.M.M.G., L.M.G., S.L., D.C.W., D.M.Z.); Dipartimento Farmaco Chimico Tecnologico, Universita'delgi Studi di Siena, Siena, Italy (G.C., V.N.); and Department of Hematology, Institute of Molecular Medicine, Trinity Centre, St. James's Hospital, Dublin, Ireland (M.L.)

Overexpression of the Bcl-2 proto-oncogene in tumor cells confers resistance against chemotherapeutic drugs. In this study, we describe how the novel pyrrolo-1,5-benzoxazepine compound 7-[{dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) selectively induces apoptosis in Bcl-2-overexpressing cancer cells, whereas it shows no cytotoxic effect on normal peripheral blood mononuclear cells. PBOX-6 overcomes Bcl-2-mediated resistance to apoptosis in chronic myelogenous leukemia (CML) K562 cells by the time- and dose-dependent phosphorylation and inactivation of antiapoptotic Bcl-2 family members Bcl-2 and Bcl-XL. PBOX-6 also induces Bcl-2 phosphorylation and apoptosis in wild-type T leukemia CEM cells and cells overexpressing Bcl-2. This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. In addition, PBOX-6 induces Bcl-2 phosphorylation and apoptosis in wild-type Jurkat acute lymphoblastic leukemia cells and cells overexpressing Bcl-2. However, Jurkat cells containing a Bcl-2 triple mutant, whereby the principal Bcl-2 phosphorylation sites are mutated to alanine, demonstrate resistance against Bcl-2 phosphorylation and apoptosis. PBOX-6 also induces the early and transient activation of c-Jun NH2-terminal kinase (JNK) in CEM cells. Inhibition of JNK activity prevents Bcl-2 phosphorylation and apoptosis, implicating JNK in the upstream signaling pathway leading to Bcl-2 phosphorylation. Collectively, these findings identify Bcl-2 phosphorylation and inactivation as a critical step in the apoptotic pathway induced by PBOX-6 and highlight its potential as an effective antileukemic agent.


Received February 25, 2004; accepted May 12, 2004.

Address correspondence to: Dr. Daniela Zisterer, Department of Biochemistry, Trinity College, Dublin 2, Ireland. E-mail: dzistrer{at}tcd.ie




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
L. M. Greene, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer
BubR1 Is Required for a Sustained Mitotic Spindle Checkpoint Arrest in Human Cancer Cells Treated with Tubulin-Targeting Pyrrolo-1,5-Benzoxazepines
Mol. Pharmacol., February 1, 2008; 73(2): 419 - 430.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Greene, L. Kelly, V. Onnis, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer
STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 288 - 297.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. M. Mulligan, L. M. Greene, S. Cloonan, M. M. Mc Gee, V. Onnis, G. Campiani, C. Fattorusso, M. Lawler, D. C. Williams, and D. M. Zisterer
Identification of Tubulin as the Molecular Target of Proapoptotic Pyrrolo-1,5-benzoxazepines
Mol. Pharmacol., July 1, 2006; 70(1): 60 - 70.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.